Paradox Immunotherapeutics is an pharmaceutical company developing immunotherapies for rare diseases using a proven-successful immunotherapy drug design platform. We design drugs that harness the body’s own immune system to clear lethal deposits from affected organs and reverse organ damage. Our team has a successful history in designing drug candidates for amyloidosis and taking them from bench to bedside.
Using the same platform technology, our lead candidate includes a potential treatment for immunoglobulin light chain (AL) cardiac amyloidosis. Their other discovery pipelines include treatments for chronic renal failure and neurodegenerative diseases. With a team of experts in immunotherapy drug design, they possess an orphan drug discovery platform, termed "The PARADOX Platform" for the potential treatment of ~30 rare diseases, a platform technology which has already sparked the interest of major players in the pharmaceutical industry.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 100 College St, Toronto,ontario M5g 1l5,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.paradoximmuno.com
- Keywords
- Representative jobs.
- HQ
- Toronto, Ontario
Paradox Immunotherapeutics Questions
Paradox Immunotherapeutics's website is http://www.paradoximmuno.com
Paradox Immunotherapeutics's LinkedIn profile is https://ca.linkedin.com/company/paradoximmuno
Paradox Immunotherapeutics has
11 employees.
View email and phone details for 11
employees at Paradox Immunotherapeutics.
Paradox Immunotherapeutics's industry is
Biotechnology Research
Paradox Immunotherapeutics's top competitors are
Symbiosis,
Dalriada Drug Discovery,
Tenomix Inc.,
Hdax Therapeutics,
Seragene Therapeutics,
9bio Therapeutics,
Noa Therapeutics,
Ripple Therapeutics,
Virica Biotech,
Obio.
Paradox Immunotherapeutics's categories are Biotechnology Research
Paradox Immunotherapeutics's founding year is 2019
